MedPath

Studying effect of propofol and ketamine as induction agents in electro convulsive therapy in patients with depression.

Phase 4
Conditions
Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features
Registration Number
CTRI/2024/03/064547
Lead Sponsor
Kapuri Manasa
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients of both sexes between age 18-65 years.

Patients with severe depressive disorder requiring electro convulsive therapy.

Patients with American Society of Anaesthesiology (ASA) physical status l & ll .

Exclusion Criteria

Pregnant females and lactating mothers.

Patients on chronic opiate use such as tramadol.

Known allergies to study drugs.

Patients with hypertension, IHD and other heart diseases.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
A) <br/ ><br>1)Mean blood pressure <br/ ><br>2)Heart rate <br/ ><br>3)Oxygen Saturation <br/ ><br>B) <br/ ><br>1)Spontaneous eye opening <br/ ><br>2)Obeying verbal commands <br/ ><br>C) <br/ ><br>MADRS(Montgomery Asberg Depression Rating Scale)Timepoint: A) <br/ ><br>2min before premedication <br/ ><br>2min after induction <br/ ><br>5min, 10min, 15min, 20min after giving shock and onset of seizures <br/ ><br>B) <br/ ><br>0min, 5min,10min, 15min post ect <br/ ><br>C) <br/ ><br>1st & 2nd week post ect
Secondary Outcome Measures
NameTimeMethod
Incidence & severity of post ect agitationTimepoint: 15 min post ect;Incidence & severity of post ect myalgiaTimepoint: 6hrs & 12hrs post ect;Seizure durationTimepoint: 10 min after induction
© Copyright 2025. All Rights Reserved by MedPath